Evaluating the Immunopathogenesis of Diabetes after Acute Pancreatitis in the D iabetes RE lated to A cute Pancreatitis and Its M echanisms Study: From the Type 1 Diabetes in Acute Pancreatitis Consortium

Type 1 Diabetes in Acute Pancreatitis Consortium (T1DAPC)

doi:10.1097/mpa.0000000000002076

Evaluating the Immunopathogenesis of Diabetes after Acute Pancreatitis in the D iabetes RE lated to A cute Pancreatitis and Its M echanisms Study: From the Type 1 Diabetes in Acute Pancreatitis Consortium

Type 1 Diabetes in Acute Pancreatitis Consortium (T1DAPC)

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

ABSTRACT: The association between acute pancreatitis (AP) and diabetes mellitus (DM) has long been established, with the initial descriptions of AP patients presenting with DM after a bout of AP published in the 1940s and 50s. However, the potential mechanisms involved, particularly those components related to the immune system, have not been well defined. The Diabetes RElated to Acute pancreatitis and its Mechanisms (DREAM) study is a multicenter clinical study designed to understand the frequency and phenotype of DM developing after AP. This article describes one objective of the DREAM study: to determine the immunologic mechanisms of DM after AP, including the contribution of β-cell autoimmunity. This component of the study will assess the presence of islet autoimmunity, as well as the magnitude and kinetics of the innate and adaptive immune response at enrollment and during longitudinal follow-up after 1 or more episodes of AP. Finally, DREAM will evaluate the relationship between immune features, DM development, and pancreatitis etiology and severity.

Original language	English (US)
Pages (from-to)	580-585
Number of pages	6
Journal	Pancreas
Volume	51
Issue number	6
DOIs	https://doi.org/10.1097/mpa.0000000000002076
State	Published - Jul 1 2022

Bibliographical note

Funding Information:
The T1DAP Consortium is funded by the National Institute of Diabetes and Digestive and Kidney Diseases (grants U01DK127384, U01DK127367, U01DK127377, U01DK127392, U01DK127382, U01DK127403, U01DK127404, U01DK127388, U01DK127395, U01DK127378, and U01DK127400). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Funding Information:
J.A.H. consults for aTyr Pharma. F.G.S.T. has received consulting fees from Sanofi, Eli Lilly, and AstraZeneca and research support from Dompé. G.I.P. has <5% equity with Ariel Precision Medicine, has consulted with Nestle, and receives research funds from Abbvie. M.D.B. receives research support from Viacyte and Dexcom and has participated on an advisory board with Insulet. C.S. participates on an advisory board for Vertex Pharmaceuticals. The rest of the authors declare no conflict of interest.

Publisher Copyright:
© Wolters Kluwer Health, Inc. All rights reserved.

Keywords

RNAseq
T1D
autoantibody
autoimmune
diabetes
immune system
Acute Disease
Humans
Insulin-Secreting Cells
Diabetes Mellitus, Type 1/complications
Pancreatitis/complications

PubMed: MeSH publication types

Multicenter Study
Journal Article
Research Support, N.I.H., Extramural

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1097/mpa.0000000000002076

Find It

Find It at U of M Libraries

Fingerprint

Dive into the research topics of 'Evaluating the Immunopathogenesis of Diabetes after Acute Pancreatitis in the D iabetes RE lated to A cute Pancreatitis and Its M echanisms Study: From the Type 1 Diabetes in Acute Pancreatitis Consortium'. Together they form a unique fingerprint.

Cite this

Evaluating the Immunopathogenesis of Diabetes after Acute Pancreatitis in the D iabetes RE lated to A cute Pancreatitis and Its M echanisms Study: From the Type 1 Diabetes in Acute Pancreatitis Consortium. / Type 1 Diabetes in Acute Pancreatitis Consortium (T1DAPC).
In: Pancreas, Vol. 51, No. 6, 01.07.2022, p. 580-585.

Research output: Contribution to journal › Article › peer-review

@article{8b43543b19d2496a856f45d243aaf807,

title = "Evaluating the Immunopathogenesis of Diabetes after Acute Pancreatitis in the D iabetes RE lated to A cute Pancreatitis and Its M echanisms Study: From the Type 1 Diabetes in Acute Pancreatitis Consortium",

abstract = "ABSTRACT: The association between acute pancreatitis (AP) and diabetes mellitus (DM) has long been established, with the initial descriptions of AP patients presenting with DM after a bout of AP published in the 1940s and 50s. However, the potential mechanisms involved, particularly those components related to the immune system, have not been well defined. The Diabetes RElated to Acute pancreatitis and its Mechanisms (DREAM) study is a multicenter clinical study designed to understand the frequency and phenotype of DM developing after AP. This article describes one objective of the DREAM study: to determine the immunologic mechanisms of DM after AP, including the contribution of β-cell autoimmunity. This component of the study will assess the presence of islet autoimmunity, as well as the magnitude and kinetics of the innate and adaptive immune response at enrollment and during longitudinal follow-up after 1 or more episodes of AP. Finally, DREAM will evaluate the relationship between immune features, DM development, and pancreatitis etiology and severity.",

keywords = "RNAseq, T1D, autoantibody, autoimmune, diabetes, immune system, Acute Disease, Humans, Insulin-Secreting Cells, Diabetes Mellitus, Type 1/complications, Pancreatitis/complications",

author = "{Type 1 Diabetes in Acute Pancreatitis Consortium (T1DAPC)} and Anna Casu and Grippo, {Paul J.} and Clive Wasserfall and Zhaoli Sun and Linsley, {Peter S.} and Hamerman, {Jessica A.} and Fife, {Brian T.} and Adam Lacy-Hulbert and Toledo, {Frederico G.S.} and Hart, {Phil A.} and Papachristou, {Georgios I.} and Bellin, {Melena D.} and Dhiraj Yadav and Laughlin, {Maren R.} and Goodarzi, {Mark O.} and Cate Speake",

note = "Funding Information: The T1DAP Consortium is funded by the National Institute of Diabetes and Digestive and Kidney Diseases (grants U01DK127384, U01DK127367, U01DK127377, U01DK127392, U01DK127382, U01DK127403, U01DK127404, U01DK127388, U01DK127395, U01DK127378, and U01DK127400). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Funding Information: J.A.H. consults for aTyr Pharma. F.G.S.T. has received consulting fees from Sanofi, Eli Lilly, and AstraZeneca and research support from Domp{\'e}. G.I.P. has <5% equity with Ariel Precision Medicine, has consulted with Nestle, and receives research funds from Abbvie. M.D.B. receives research support from Viacyte and Dexcom and has participated on an advisory board with Insulet. C.S. participates on an advisory board for Vertex Pharmaceuticals. The rest of the authors declare no conflict of interest. Publisher Copyright: {\textcopyright} Wolters Kluwer Health, Inc. All rights reserved.",

year = "2022",

month = jul,

day = "1",

doi = "10.1097/mpa.0000000000002076",

language = "English (US)",

volume = "51",

pages = "580--585",

journal = "Pancreas",

issn = "0885-3177",

publisher = "Lippincott Williams and Wilkins",

number = "6",

}

TY - JOUR

T1 - Evaluating the Immunopathogenesis of Diabetes after Acute Pancreatitis in the D iabetes RE lated to A cute Pancreatitis and Its M echanisms Study

T2 - From the Type 1 Diabetes in Acute Pancreatitis Consortium

AU - Type 1 Diabetes in Acute Pancreatitis Consortium (T1DAPC)

AU - Casu, Anna

AU - Grippo, Paul J.

AU - Wasserfall, Clive

AU - Sun, Zhaoli

AU - Linsley, Peter S.

AU - Hamerman, Jessica A.

AU - Fife, Brian T.

AU - Lacy-Hulbert, Adam

AU - Toledo, Frederico G.S.

AU - Hart, Phil A.

AU - Papachristou, Georgios I.

AU - Bellin, Melena D.

AU - Yadav, Dhiraj

AU - Laughlin, Maren R.

AU - Goodarzi, Mark O.

AU - Speake, Cate

N1 - Funding Information: The T1DAP Consortium is funded by the National Institute of Diabetes and Digestive and Kidney Diseases (grants U01DK127384, U01DK127367, U01DK127377, U01DK127392, U01DK127382, U01DK127403, U01DK127404, U01DK127388, U01DK127395, U01DK127378, and U01DK127400). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Funding Information: J.A.H. consults for aTyr Pharma. F.G.S.T. has received consulting fees from Sanofi, Eli Lilly, and AstraZeneca and research support from Dompé. G.I.P. has <5% equity with Ariel Precision Medicine, has consulted with Nestle, and receives research funds from Abbvie. M.D.B. receives research support from Viacyte and Dexcom and has participated on an advisory board with Insulet. C.S. participates on an advisory board for Vertex Pharmaceuticals. The rest of the authors declare no conflict of interest. Publisher Copyright: © Wolters Kluwer Health, Inc. All rights reserved.

PY - 2022/7/1

Y1 - 2022/7/1

N2 - ABSTRACT: The association between acute pancreatitis (AP) and diabetes mellitus (DM) has long been established, with the initial descriptions of AP patients presenting with DM after a bout of AP published in the 1940s and 50s. However, the potential mechanisms involved, particularly those components related to the immune system, have not been well defined. The Diabetes RElated to Acute pancreatitis and its Mechanisms (DREAM) study is a multicenter clinical study designed to understand the frequency and phenotype of DM developing after AP. This article describes one objective of the DREAM study: to determine the immunologic mechanisms of DM after AP, including the contribution of β-cell autoimmunity. This component of the study will assess the presence of islet autoimmunity, as well as the magnitude and kinetics of the innate and adaptive immune response at enrollment and during longitudinal follow-up after 1 or more episodes of AP. Finally, DREAM will evaluate the relationship between immune features, DM development, and pancreatitis etiology and severity.

AB - ABSTRACT: The association between acute pancreatitis (AP) and diabetes mellitus (DM) has long been established, with the initial descriptions of AP patients presenting with DM after a bout of AP published in the 1940s and 50s. However, the potential mechanisms involved, particularly those components related to the immune system, have not been well defined. The Diabetes RElated to Acute pancreatitis and its Mechanisms (DREAM) study is a multicenter clinical study designed to understand the frequency and phenotype of DM developing after AP. This article describes one objective of the DREAM study: to determine the immunologic mechanisms of DM after AP, including the contribution of β-cell autoimmunity. This component of the study will assess the presence of islet autoimmunity, as well as the magnitude and kinetics of the innate and adaptive immune response at enrollment and during longitudinal follow-up after 1 or more episodes of AP. Finally, DREAM will evaluate the relationship between immune features, DM development, and pancreatitis etiology and severity.

KW - RNAseq

KW - T1D

KW - autoantibody

KW - autoimmune

KW - diabetes

KW - immune system

KW - Acute Disease

KW - Humans

KW - Insulin-Secreting Cells

KW - Diabetes Mellitus, Type 1/complications

KW - Pancreatitis/complications

UR - http://www.scopus.com/inward/record.url?scp=85139570875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85139570875&partnerID=8YFLogxK

U2 - 10.1097/mpa.0000000000002076

DO - 10.1097/mpa.0000000000002076

M3 - Article

C2 - 36206462

AN - SCOPUS:85139570875

SN - 0885-3177

VL - 51

SP - 580

EP - 585

JO - Pancreas

JF - Pancreas

IS - 6

ER -

Evaluating the Immunopathogenesis of Diabetes after Acute Pancreatitis in the D iabetes RE lated to A cute Pancreatitis and Its M echanisms Study: From the Type 1 Diabetes in Acute Pancreatitis Consortium

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this